Very strange, J&J mucked around with the trial so it's no longer statistically significant.
AND, they mucked with it when the drug doesn't show any survival advantage until after 18 months (when the stuff is only given for 14 months)
And, this is the wonder drug that's killing Provenge?
the prostate cancer drug story just gets stranger and stranger....
http://seekingalpha.com/article/634...rgue-for-sequencing-dendreon-s-provenge-first
AND, they mucked with it when the drug doesn't show any survival advantage until after 18 months (when the stuff is only given for 14 months)
And, this is the wonder drug that's killing Provenge?
the prostate cancer drug story just gets stranger and stranger....
http://seekingalpha.com/article/634...rgue-for-sequencing-dendreon-s-provenge-first
NDN) are falling Monday. The latter firm has its own prostate treatment, Provenge, and the good news for Zytiga is thought by analysts to be bad for Dendreon’s prospects. Roth Capital now thinks that Provenge is in greater danger of losing market share, and thus has sharply lowered its price target on Dendreon from $12 to $6.70, keeping its Neutral rating on the shares. Jefferies piles on, saying that Provenge might become a niche drug due to competition from Johnson & Johnson and Medivation (NASDAQ:MDVN), which has developed its own prostate cancer treatment, MDV3100. Jefferies keeps its $5 target and Underperform rating on Dendreon shares.